Effects of acute and chronic triazolam treatments on brain GABA levels in albino rats

• Autorzy: Aburawi S M , Elhuwuegi A.S. , Ahmed S.S. , Saad S.F. , Attia A.S.
• Języki publikacji: EN

Abstrakty

EN

The present study investigated the effects of acute and chronic intraperitoneal administration of Triazolam on g-aminobutyric acid (GABA) levels in different brain areas of albino rats. Three experiments were conducted. In the first, five groups of rats were acutely treated with different doses of Triazolam (0.25 mg/kg-4.0 mg/kg). In the second experiment, rats were treated chronically with a single daily dose of Triazolam (started with 0.25 mg/kg and increased by time to 1.0 mg/kg) for 5 weeks, simulating clinical use. In the third, rats were treated chronically with three daily doses of Triazolam (started with 0.25 mg/kg and increased by time to 0.5 mg/kg) for 20 days, representing a form of drug abuse. Brain levels of GABA and plasma levels of Triazolam were measured using high performance liquid chromatography (HPLC). The acute Triazolam administration produced an increase in GABA levels in all brain areas studied. The chronic administration of single daily dose of Triazolam produced normal GABA levels in all brain areas except brain stem where the levels were significantly decreased; this indicates the development of tolerance to Triazolam action on increasing GABA content. The chronic administration of three daily doses of Triazolam produced a decrease in GABA levels in all brain regions studied. In conclusion, chronic single daily dose treatment (representing normal use) produces tolerance to Triazolam effects on brain GABA levels, while chronic three daily doses administration (akin to drug abuse) causes a fall in GABA levels.

Słowa kluczowe

EN

triazolam; albino rat; brain; treatment; drug; neurotransmission; tolerance; high performance liquid chromatography; gamma-aminobutyric acid

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2000
• Tom: 60
• Numer: 4
• Opis fizyczny: p.447-455

Twórcy

autor

Aburawi S M

• Great Alfateh University of Medical Sciences, Tripoli, Libya

autor

Elhuwuegi A.S.

autor

Ahmed S.S.

autor

Saad S.F.

autor

Attia A.S.

Bibliografia

• Abdel-Hamid M. E., Abuirjeie M. A. (1988) Determination of diazepam and oxazepam using high-performance liquid chromatography and fourth-derivative spectrophotometry techniques. Analys. 113: 1443-1446.
• Assandri A., Bernareggi A., Barone D., Odasso G. (1984) Pharmacokinetics of premazepam, a new anti-anxiety pyrrolodiazepine, in the rat and the dog. Drugs Exptl. Clin. Res. X: 241-251.
• Brown M. J., Bristow D. R. (1996) Molecular mechanisms of benzodiazepine-induced down-regulation of GABAA re­ceptor ai-subunit protein in rat cerebellar granule cells. Br. J.Pharmacol. 118: 1103-1110.
• Burt D. R., Kamatchi G. L. (1991) GABA receptor subtypes from pharmacology to molecular biology. FASEB J. 5: 2916-2923.
• Cash D. J., Serfozo P., Allan A. M. (1997) Desensitization of a gamma-aminobutyric acid type A receptor in rat is in­creased by chronic treatment with chlordiazepoxide: a mo­lecular mechanism of dependence. J. Pharmacol. Exp. Ther. 283: 704-711.
• Choi D.W., Farb D.H., Fischbach G.D. (1981) Chlordiaze- poxide selectively potentiates GABA conductance of spi­nal cord and sensory neurons in cell culture. J. Neurophysiol. 45: 621-631.
• Collado M. C., Beleta J., Martinez E., Miralpeix M., Domenech T., Palacios J. M., Hernandez J. (1998) Func­tional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor. Br. J. Pharmacol. 123: 1047-1054.
• Collier H. O. J. (1966) Tolerance, physical dependence andre- ceptors: a theory of genesis of tolerance and physical de­pendence through drug-induced changes in the number of receptors. Adv. Drug Res. 3: 171-188.
• Collinge J., Pycock C. J., Taberner P. V. (1983) Studies on the interaction between cerebral 5-hydroxytryptamine and y-aminobutyric acid in the mode of action of DZ in the rat. Br. J. Pharmacol. 79: 637-643.
• Costa E., Guidotti A. (1996) Benzodiazepines on trial: a re­search strategy for their rehabilitation. TIPS 17: 192-199.
• Cumin R., Bonetti E. P., Scherschlicht R., Haefely W. E. (1982) Use of the specific benzodiazepine antagonist, Ro 15-1788, in studies of physiological dependence on benzodiazepines. Experientia 38: 833-834.
• Edwards G., Arif A., Hodgson R. (1981) Nomenclature and classification of drug- and alcohol- related problems. A WHO memorundum, Bull. WHO. 59: 225-242.
• File S. E. (1985) Tolerance to the behavioural actions of benzodiazepines. Neurosci. Behav. Rev. 9: 113-121.
• Giusti P., Ducic I., Puia G., Arban R., Walser A., Guidotti A., Costa E. (1993) Imidazenil, a new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABAa receptors. J. Pharmacol. Exp. Ther. 266:1018-1028.
• Goldstein A., Goldstein D. B. (1968) Enzyme expansion the­ory of drug tolerance and physical dependence. Proc. Assoc. Res. Nerv. Ment. Dis. 45: 265-267.
• Gonsalves S. F., Gallager D. W. (1985) Spontaneous and Ro 15-1788-induced reversal of subsensitivity to GABA fol­lowing chronic benzodiazepines. Eur. J. Pharmacol. 110: 163-170.
• Haefely W. (1978) Central actions of benzodiazepines: gen­eral introduction. Br. J. Psychiatry 133: 231-238.
• Haefely W. E. (1990) The GABAA-benzodiazepine receptor: biology and pharmacology. In: Handbook of anxiety. The neurobiology of anxiety (Eds. G.D. Burrows M., Roth R. and Jr. Noyes). Vol. 3. Elsevier Science Publishers B. V.
• Heninger C., Saito N., Tallman J. F., Garrett K. M., Vitek M. P., Duman R. S., Gallager D. W. (1990) Effects of continu­ous diazepam administration on GABAA subunit mRNA in rat brain. J. Mol. Neurosci. 2: 101-107.
• Hitchcott P. K., File S. E., Fkwurn M., Neal M. J. (1990) Chronic diazepam treatment in rats causes long-lasting changes in central [3H] - 5-hydroxytryptamine and [14C]-(y-aminobutyric acid release. Br. J. Pharmacol. 99: 11-12.
• Hu X. J., Ticku M. K. (1994) Chronic flurazepam treatment produces decreased efficacy of the benzodiazepine lig- ands and pentobarbital with y-aminobutyric acidA recep­tors in cortical neurons. J. Pharmacol. Exp. Ther. 270: 485-490.
• Impagnatiello F., Pesold C., Longone P. (1996) Modifications of y-aminobutyric acid(A) receptor subunit expression in rat neocortex during tolerance to diazepam. Mol. Pharmacol. 49: 822-831.
• Jaffe J. H., Sharpless. S. K. (1968) Pharmacological denervation supersensitivity in the central nervous system: a theory of physical dependence. Proc. Assoc. Res. Nerv. Ment. Dis. 46: 226-246.
• Koe B. K. (1979) Biochemical effects of antianxiety drugs on brain monoamines. In: Anxiolytics (Eds. S. Fielding and H. Lal). Vol. 3. Futura, New York, p. 173-195.
• Koob G., Bloom F. (1988) Cellular and molecular mecha­nisms of drug dependence. Science 242: 715-723.
• Krueger K.E., Papadopoulos V. (1992) Mitochondrial benzo­diazepine receptors and steroid biosynthesis. Annu. Rev. Pharmacol. Toxicol. 32: 211-237.
• MajewskaM. D., HarrisonN. L., Schwartz R. D., Barker J. L., Paul S. M. (1986) Steroid hormone metabolites arebarbiturate-like modulators of the GABA receptor. Science 232: 1004-1007.
• Martin W. R. (1968) A homeostatic and redundancy theory of tolerance to and dependence on narcotic analgesics. Proc. Assoc. Res. Ner. Ment. Dis. 46: 206-225.
• Miller L. G., Greenblatt D. J., Roy R. B., Summer W. R., ShaderR. I. (1988) Chronic benzodiazepine administra­tion. II. Discontinuation syndrome is associated with up­grading of y-aminobutyric acidA receptor complex binding and function. J. Pharm. Exp. Ther. 246: 177-182.
• Miller L. G., Greenblatt D. J., Shader R. I. (1987) Receptor downregulation is associated with tolerance to benzodiazepines. Clin. Res. 35: 579.
• Morrow A. L., Pace J. R., Purdy R. H., Paul S. M. (1990) Char­acterization of steroid interactions with y-aminobutyric acid receptor-gated chloride ion channels: Evidence for multiple steroid recognition sites. Mol. Pharmacol. 37: 263-270.
• NowakowskaE., ChoderaA., KusK. (1997) Pharmacological aspects of withdrawal from certain benzodiazepines. Pol. J. Pharmacol. 49: 89-95.
• Otero Losada M. E. (1988) Changes in central GABAergic function following acute and repeated stress. Br. J. Pharmacol. 93: 483-490.
• Otero Losada M. E. (1989) Acute stress and GABAergic func­tion in the rat brain. Br. J. Pharmacol. 96: 507-512.
• Paul S.M., Marangos P.S., Skolnick P. (1981) The benzodiaz- epine-GABA-chloride ionophore receptor complex: com­mon site for minor tranquilizer action. Biol. Psychiat. 16: 213-229.
• Perkins J. P., Hausdorff W. P., Lefkowitz R. J. (1991) Mecha­nism of ligand-induced desensitization of P-adrenergic re­ceptors. In: The P-adrenergic receptors (Ed: J. P. Perkins). The Humana Press, Clifton, NJ, p. 73-124.
• Polc P. (1988) Electrophysiology of benzodiazepine receptor ligands: multiple mechanisms and sites of action. Prog. Neurobiol. 31: 349-423.
• Potokar J., Nutt D. J. (1994) Anxiolytic potential of benzodiazepines receptor partial agonists. CNS Drugs. 1: 305-315.
• Pratt J. A., Brett R. R., Laurie D. J. (1998) Benzodiazepine de­pendence: from neural circuits to gene expression. Pharmacol. Biochem. Behav. 59: 925-934.
• Puia G., Santi M. R., Vicini S., Pritchett D. B., Purdy R. H. (1990) Neurosteroids act on recombinant human GABAA receptors. Neuron 4: 759-765.
• Purdy R. H., Morrow A. L., Moore P. H. (1991) Stress-in­duced elevations of y-aminobutyric acid type A recep­tor-active steroids in the rat brain. Proc. Natl. Acad. Sci. USA. 88: 4553-4557.
• Reddy D. S., Kulkarni S. K. (1997a) Neurosteroid coadmini- stration prevents development of tolerance and augments recovery from benzodiazepine withdrawal anxiety and hy- peractivity in mice. Methods. Find. Exp. Clin. Pharmacol. 19: 395-405.
• Reddy D. S., Kulkarni S. K. (1997b) Reversal of benzodiaz- epine inverse agonist FG 7142-induced anxiety syndrome by neurosteroids in mice. Methods. Find. Exp. Clin. Pharmacol. 19: 665-681.
• Rodgers R. J., Johnson N. J. (1998) Behaviorally selective ef­fects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol. Biochem. Behav. 59: 221-232.
• Saad S. F. (1972) Effect of diazepam on y-aminobutyric acid (GABA) content of mouse brain. J. Pharm. Pharmac. 24: 848-850.
• Saad S. F., Fahim A. T., Attia A. S., Seif El-Nasr M. (1995) Changes in mouse brain y-aminobutyrate metabolism dur­ing lorazepam induced abstinence syndromes. Med. Sci. Res. 23: 465-467.
• Saller C. F., Czupryna M. J. (1989) y-Aminobutyric acid, glutamic, glycine and taurine analysis using reversed-phase high-performance liquid chromatography and ultraviolet detection of dansyl chloride derivatives. J. Chromatogr. 487: 167-172.
• Scharf M.B., Feile P. (1983) Acute effects of drug administra­tion and withdrawal on the benzodiazepine receptor. Life Sci. 32: 1771-1777.
• Schmith V. D. (1991) New high-performance liquid chro- matographic method for the determination of alprazolam and its metabolites in serum: instability of 4-hydro- xyalprazolam. J. Chromatogr. 568: 253-260.
• SchmidR., KarobathM. (1977) Specific and sensitive method for the determination of y-aminobutyric acid using gas chromatography with electron-capture or mass fragmento- graphic detection. J. Chromatogr. 139: 101-109.
• Shuster L. (1971) Tolerance and physical dependence. In: Narcotic drugs: biochemical pharmacology (Ed. D. H. Clouet). Plenum Press, New York, p. 408-423.
• Tietz E. I., Rosenberg H. C., Chiu T. H. (1986) Autoradiographic localization of benzodiazepine receptor downregulation. J. Pharmacol. Exp. Ther. 236: 284-291.
• Wieland S., Belluzzi J., Hawkinson J. E., Hogenkamp D., Upasani R., Stein L., Wood P. L., Gee K. W., Lan N. C. (1997) Anxiolytic and anticonvulsant activity of a syn­thetic neuroactive steroid Co 3-0593. Psychopharma- cology-Berl. 134: 46-54.
• Zecca L., Zambotti F., Zonta N., Mantegazza P. (1982) Deter­mination of y-aminobutyric acid in brain areas by high-performance liquid chromatography of dansyl deriva­tives with ultraviolet detection. J. Chromatogr. 238: 307-312.
• Zhao K. J., Chiu T. H., Rosenberg H. C. (1994) Reduced ex­pression of y-aminobutyric acid type A/benzodiazepine re­ceptor y2 and a5 subunit mRNAs in brain regions of flurazepam-treated rats. Mol. Pharmacol. 45: 657-663.